Araclon Biotech

ADPD 2025

We are thrilled to announce our participation in the upcoming AD/PD 2025 Congress in Vienna (April 1-5) // Join us at AD/PD2025 Congress in Vienna (April 1-5)

This hybrid event will unite experts and leaders from the health, neuroscience, and biotechnology sectors to discuss the latest advancements in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as in their diagnosis and treatment.

OUR MISSION

Araclon Biotech, a subsidiary of Grifols, is a company specialising in the research and development of methods for the early diagnosis and preventive treatment of Alzheimer’s disease.

AIDING THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE

We are pioneers in the development of assays based on the determination of amyloid peptides in plasma that help to detect early pathological changes of the disease, before the onset of symptoms.

RESEARCH INTO THE TREATMENT OF ALZHEIMER'S DISEASE

We are developing ABvac40, an active vaccine to prevent the disease or delay the onset of symptoms.